Compare Novo Nordisk A/S (NVO) vs Vanguard International High Dividend Yield ETF (VYMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Vanguard International High Dividend Yield ETF — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while Vanguard International High Dividend Yield ETF trades at $100.66 (market cap $22.80B). The key difference: Novo Nordisk A/S is far larger — about 7.3× Vanguard International High Dividend Yield ETF's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Vanguard International High Dividend Yield ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Vanguard International High Dividend Yield ETF for 50 Days on average.
| NVO | VYMI | |
|---|---|---|
Market Cap | $165.31B | $22.80B |
Volume | 11,432,838 | 748,441 |
Sector | Health | Broad Market / Factor |
52-Week High | $63.98 | $107.13 |
52-Week Low | $35.29 | $82.92 |
Typical Hold Time | 116 Days | 50 Days |
Enterprise Value | $179.56B | — |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
VYMI trades at $100.66, up 0.43% on the day, with a bearish technical signal from moving averages but neutral oscillators. The ETF focuses on international high dividend yield stocks, with recent institutional buying activity from Envestnet and Corient Private Wealth. Recent news highlights strong performance with a 29% one-year return and 14.13% five-year average annual return, supported by financials, energy, and healthcare sector exposure.
The outlook remains positive given Vanguard's bullish stance on international developed markets and the ETF's attractive dividend yield. Key risks include global economic volatility and currency fluctuations, but institutional accumulation and sector alignment with rising rates support the investment thesis for income-focused investors seeking international diversification.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Vanguard International High Dividend Yield ETF
VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →
